ImmunoGen Gets FDA Priority Review of Mirvetuximab Soravtansine in Ovarian Cancer
23 May 2022 - 9:09PM
Dow Jones News
By Colin Kellaher
ImmunoGen Inc. on Monday said the U.S. Food and Drug
Administration granted priority review to its application for
mirvetuximab soravtansine monotherapy in certain patients with
ovarian cancer.
The Waltham, Mass., biotechnology company is seeking approval of
mirvetuximab soravtansine in patients with folate receptor
alpha-high platinum-resistant ovarian cancer who have previously
received one to three systemic treatments.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review period.
ImmunoGen said the agency set a target action date of Nov. 28 for
the application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 23, 2022 06:54 ET (10:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024
